TradingView
AlenCiken
3 de Feb. de 2019 21:51

Marinus Announces Successful Clinical Trial Results 

NASDAQ:MRNS1D
Marinus Pharmaceuticals, Inc.NASDAQ

Descripción

⋅
top-line data from the Phase 2 open-label study in patients with CDKL5 disorder support advancing ganaxolone into a definitive late-stage clinical trial.

globenewswire.com/news-release/2017/09/11/1117414/0/en/Marinus-Announces-Successful-Clinical-Trial-Results-and-Declares-CDKL5-Disorder-Its-Lead-Pediatric-Orphan-Epilepsy-Program-for-Ganaxolone.html

Trend AnalysisChart PatternsTechnical Indicators
Más